{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["16"],"submitter":["Spagnuolo V"],"pubmed_abstract":["<h4>Background</h4>Evidence regarding the impact of remdesivir (RDV) on SARS-CoV-2 viral clearance (VC) is scarce. The aim of this study was to compare VC timing in hospitalized COVID-19 patients who did or did not receive RDV.<h4>Methods</h4>This was a matched-cohort study of patients hospitalized with pneumonia, a SARS-CoV-2-positive nasopharyngeal swab (NPS) at admission, and at least one NPS during follow-up. Patients who received RDV (cases) and those who did not (controls) were matched in a 1:2 ratio by age, sex, and PaO<sub>2</sub>/FiO<sub>2</sub> (P/F) values at admission. NPSs were analyzed using real-time polymerase chain reaction. Time to VC (within 30 days after hospital discharge) was estimated using the Kaplan-Meier curve. A multivariable Cox proportional hazard model was fit"],"journal":["Drug design, development and therapy"],"pagination":["3645-3654"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9578770"],"repository":["biostudies-literature"],"pubmed_title":["Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study."],"pmcid":["PMC9578770"],"pubmed_authors":["Racca S","Bruzzesi E","Dagna L","Tonelli M","Zangrillo A","Clementi N","Spagnuolo V","Poli A","Clementi M","Voarino M","COVID-BioB Study Group","Rovere Querini P","Ciceri F","Oltolini C","Tresoldi M","Castagna A","Galli L"],"additional_accession":[]},"is_claimable":false,"name":"Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study.","description":"<h4>Background</h4>Evidence regarding the impact of remdesivir (RDV) on SARS-CoV-2 viral clearance (VC) is scarce. The aim of this study was to compare VC timing in hospitalized COVID-19 patients who did or did not receive RDV.<h4>Methods</h4>This was a matched-cohort study of patients hospitalized with pneumonia, a SARS-CoV-2-positive nasopharyngeal swab (NPS) at admission, and at least one NPS during follow-up. Patients who received RDV (cases) and those who did not (controls) were matched in a 1:2 ratio by age, sex, and PaO<sub>2</sub>/FiO<sub>2</sub> (P/F) values at admission. NPSs were analyzed using real-time polymerase chain reaction. Time to VC (within 30 days after hospital discharge) was estimated using the Kaplan-Meier curve. A multivariable Cox proportional hazard model was fit","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T21:01:09.103Z","creation":"2024-11-12T14:17:21.334Z"},"accession":"S-EPMC9578770","cross_references":{"pubmed":["36268521"],"doi":["10.2147/DDDT.S369473"]}}